Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3614-3621

  Engel, Jörg B ^a,b   Keller, Gunhild ^a,b   Schally, Andrew V ^a,b   Toller, Gabor L ^a,b   Groot, Kate ^a,b   Havt, Alexandre ^a,b   Armatis, Patricia ^a,b   Zarandi, Marta ^a,b   Varga, Jozsef L ^a,b   Halmos, Gabor ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; JV 1 42; MESSENGER RNA; MZ J 7 118; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN A; MZ-J-7-118; SERMORELIN; SOMATOMEDIN B; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CELL DIVISION; DRUG ANTAGONISM; ENDOMETRIUM TUMOR; KINETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

MUS MUSCULUS;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KINETICS; MICE; MICE, KNOCKOUT; SERMORELIN; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21244491227     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2179     Document Type: Article

References (55)

1. Creasman WT 1997 Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 24(Suppl 1):S1-140-S1-50
2. Bristow RE 1999 Endometrial cancer. Curr Opin Oncol 11:388-393
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ 2003 Cancer statistics, 2003. CA Cancer J Clin 53:5-26
4. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S 2001 Carcinoma of the corpus uteri. J Epidemiol Biostat 6:47-86
5. Chen LM, McGonigle KF, Berek JS 1999 Endometrial cancer: recent developments in evaluation and treatment. Oncology 13:1665-1682
6. Aalders JG, Abeler V, Kolstad P 1984 Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 17:85-103
7. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G 2001 Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248-291
8. Schally AV, Varga JL 1999 Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10:383-391
9. Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Rekasi Z 1999 Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96:692-697
10. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z, Zarandi M 2004 Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci USA 101:1708-1713
11. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G 2000 Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer 36:128-136
12. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G 2000 Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 82:1724-1731
13. Jungwirth A, Schally AV, Pinski J, Halmos G. Groot K, Armatis P, Vadillo-Buenfil M 1997 Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 75:1585-1592
14. Lamharzi N, Schally AV, Koppan M, Groot K 1998 Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 95:8864-8868
15. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou I, Czompoly T, Halmos G 2000 Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 60:71-79
16. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL 2003 Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 100:1250-1255
17. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G 1997 Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 94:5810-5813
18. Kiaris H, Schally AV, Varga JL 2000 Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2:242-250
19. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P 1995 Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 87:1787-1794
20. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P 2002 Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95:1735-1745
21. Szereday Z, Schally AV, Varga JL, Kanashiro C, Hebert F, Armatis P, Groot K, Szepeshazi K, Halmos G, Busto R 2003 Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 63:7913-7919
22. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P 1999 Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96:14894-14898
23. Pinski J SA, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M, Vaudillo-Buenfil M 1996 Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol 9:1099-1105
24. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE 2000 The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244
25. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Bajo AM 2001 Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. J Cancer Res Clin Oncol 127:645-652
26. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G 2001 Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 86:2144-2152
27. Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G 2002 Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides 23:1127-1133
28. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, Halmos G 2001 Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12:761-768
29. Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, Varga JL, Halmos G 2001 Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142:4371-4378
30. Csernus VJ, Schally AV, Kiaris H, Armatis P 1999 Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 96:3098-3103
31. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T 2000 Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. Endocrinology 141:2120-2128
32. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K 2002 The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 99:11866-11871
33. Busto R, Schally AV, Braczkowski R, Plonowski A, Krupa M, Groot K., Armatis P, Varga JL 2002 Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept 108:47-53
34. Plonowski A, Schally AV, Letsch M, Hebert F, Groot K, Varga JL 2002 Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 52:173-182
35. Frohman LA, Szabo M 1981 Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 74:259-271
36. Kahan Z, Arencibia JM, Csernus VJ, Groot K, Kineman R, Robinson WR, Schally AV 1999 Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84:582-589
37. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R 2003 The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77:15-26
38. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, Rekasi Z 2002 Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87:4707-4714
39. Benlot C, Levy L, Fontanaud P, Roche A, Rouannet P, Joubert D 1997 Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation. J Clin Endocrinol Metab 82:690-696
40. Khorram O, Garthwaite M, Grosen E, Golos T 2001 Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril 75:174-179
41. Rekasi Z, Czompoly T, Schally AV, Halmos G 2000 Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566
42. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T 2000 Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA 97:10555-10560
43. Chopin LK, Herington AC 2001 A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49:116-121
44. Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A 2003 Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 22:1141-1146
45. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga J, Koutselini H, Kalofoutis A 2003 Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 100:9512-9517
46. Kineman RD 2000 Antitumorigenic actions of growth hormone-releasing hormone antagonists. Proc Natl Acad Sci USA 97:532-534
47. Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL 2002 Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci USA 99:196-200
48. Kuramoto H, Tamura S, Notake Y 1972 Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114:1012-1019
49. Breier BH, Gallaher BW, Gluckman PD 1991 Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128:347-357
50. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
51. Munson PJ, Rodbard D 1980 Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239
52. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K 2000 Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 44:172-180
53. Pinski J, Izdebski J, Jungwirth A, Groot K, Schally AV 1996 Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats. Regul Pept 65:197-201
54. Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G 2002 Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int J Cancer 98:624-629
55. Sachdev D, Yee D 2001 The IGF system and breast cancer. Endocr Relat Cancer 8:197-209